報價延遲最少15分鐘:2026/04/03 18:14 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.24 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.32/1.47
|
|
企業價值
445.78M
|
| 資產負債 |
|
每股賬面淨值
2.78
|
| 現金流量 |
|
現金流量率
0.12
|
| 損益表 |
|
收益
94.57M
|
|
每股收益
0.49
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services. |
